|Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine|
DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ...
New England Journal of Medicine 369 (18), 1691-1703, 2013
|Core signaling pathways in human pancreatic cancers revealed by global genomic analyses|
S Jones, X Zhang, DW Parsons, JCH Lin, RJ Leary, P Angenendt, ...
science 321 (5897), 1801-1806, 2008
New England Journal of Medicine 362 (17), 1605-1617, 2010
|A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development|
A Jimeno, G Feldmann, A Suárez-Gauthier, Z Rasheed, A Solomon, ...
Molecular cancer therapeutics 8 (2), 310-314, 2009
|Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations|
DM Hyman, I Puzanov, V Subbiah, JE Faris, I Chau, JY Blay, J Wolf, ...
New England Journal of Medicine 373 (8), 726-736, 2015
|Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab|
S Khambata-Ford, CR Garrett, NJ Meropol, M Basik, CT Harbison, S Wu, ...
Journal of clinical oncology 25 (22), 3230-3237, 2007
|Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies|
M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ...
Journal of clinical oncology 19 (13), 3267-3279, 2001
|Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma|
MB Atkins, M Hidalgo, WM Stadler, TF Logan, JP Dutcher, GR Hudes, ...
Journal of clinical oncology 22 (5), 909-918, 2004
|Patient-derived xenograft models: an emerging platform for translational cancer research|
M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ...
Cancer discovery 4 (9), 998-1013, 2014
|Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial|
DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ...
Journal of Clinical Oncology 29 (34), 4548, 2011
|Development of matrix metalloproteinase inhibitors in cancer therapy|
M Hidalgo, SG Eckhardt
Journal of the National Cancer Institute 93 (3), 178-193, 2001
|DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer|
CA Iacobuzio-Donahue, B Fu, S Yachida, M Luo, H Abe, CM Henderson, ...
Journal of clinical oncology 27 (11), 1806, 2009
|Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of …|
D Soulieres, NN Senzer, EE Vokes, M Hidalgo, SS Agarwala, LL Siu
Journal of clinical oncology 22 (1), 77-85, 2004
|Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study|
E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ...
Journal of Clinical Oncology 23 (23), 5294-5304, 2005
|The rapamycin-sensitive signal transduction pathway as a target for cancer therapy|
M Hidalgo, EK Rowinsky
Oncogene 19 (56), 6680-6686, 2000
|Developing inhibitors of the epidermal growth factor receptor for cancer treatment|
V Grunwald, M Hidalgo
Journal of the National Cancer Institute 95 (12), 851-867, 2003
|Pancreatic cancer: from state-of-the-art treatments to promising novel therapies|
I Garrido-Laguna, M Hidalgo
Nature reviews Clinical oncology 12 (6), 319-334, 2015
|Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity|
LA DeGraffenried, WE Friedrichs, DH Russell, EJ Donzis, AK Middleton, ...
Clinical cancer research 10 (23), 8059-8067, 2004
|Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma|
ZA Rasheed, J Yang, Q Wang, J Kowalski, I Freed, C Murter, SM Hong, ...
Journal of the National Cancer Institute 102 (5), 340-351, 2010
|An in vivo platform for translational drug development in pancreatic cancer|
B Rubio-Viqueira, A Jimeno, G Cusatis, X Zhang, C Iacobuzio-Donahue, ...
Clinical cancer research 12 (15), 4652-4661, 2006